Accurately identify patients resistant to targeted therapies
For patients with metastatic castration-resistant prostate cancer (mCRPC), the Oncotype DX AR-V7 Nucleus Detect Test lets you quickly and confidently determine the likely benefit of androgen receptor (AR)-targeted therapies, like Abiraterone (Zytiga®), Enzalutamide (Xtandi™), and Apalutamide (Erleada™).
- Accurately identify patients who are unlikely to benefit from AR-targeted therapies.1-3
- Predict whether taxanes or AR-targeted therapies may offer improved overall survival.1,2
- Results are easy to interpret (positive or negative).
Interactive report guide
Quickly and easily understand how to interpret the AR-V7 Nucleus Detect Test report.
See sample reports
For patients with:
Getting your results
Most Oncotype DX AR-V7 Nucleus Detect Test results are available within two weeks of the date we receive your patient's sample at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.